1. Home
  2. PRAX vs MANH Comparison

PRAX vs MANH Comparison

Compare PRAX & MANH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$318.23

Market Cap

7.1B

Sector

Health Care

ML Signal

HOLD

Logo Manhattan Associates Inc.

MANH

Manhattan Associates Inc.

HOLD

Current Price

$136.29

Market Cap

7.8B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRAX
MANH
Founded
2015
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
7.1B
7.8B
IPO Year
2020
1998

Fundamental Metrics

Financial Performance
Metric
PRAX
MANH
Price
$318.23
$136.29
Analyst Decision
Strong Buy
Buy
Analyst Count
15
11
Target Price
$572.13
$209.73
AVG Volume (30 Days)
560.5K
558.0K
Earning Date
05-08-2026
04-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
2.56
EPS
N/A
0.82
Revenue
N/A
$131,300,000.00
Revenue This Year
N/A
$8.10
Revenue Next Year
$7,758.26
$8.81
P/E Ratio
N/A
$155.93
Revenue Growth
N/A
N/A
52 Week Low
$37.25
$119.06
52 Week High
$366.52
$247.22

Technical Indicators

Market Signals
Indicator
PRAX
MANH
Relative Strength Index (RSI) 57.49 48.17
Support Level $308.40 $125.34
Resistance Level $327.65 $145.24
Average True Range (ATR) 17.85 6.05
MACD 8.65 -1.43
Stochastic Oscillator 83.99 44.80

Price Performance

Historical Comparison
PRAX
MANH

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

About MANH Manhattan Associates Inc.

Manhattan Associates provides software that helps users manage their supply chains, inventory, and omnichannel operations. Customers are generally retailers, wholesalers, manufacturers, and logistics providers. The company was founded in 1990 and serves more than 1,200 customers worldwide.

Share on Social Networks: